# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $7 price target.
CNM-Au8 is an orally administered, catalytic nanotherapeutic that targets energy metabolism via mitochondria in nervous system ...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $7 price target.
Survival analyses with CNM-Au8 30 mg treatment compared to matched PRO-ACT controls demonstrated improved survival up to 3.5 ...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $7 price target.